THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
NCT ID: NCT06859710
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
30 participants
INTERVENTIONAL
2025-11-05
2028-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0 mg THC, 0 mg CBD
Placebo
Vaporized Placebo
THC
20 mg THC, 0 mg CBD
THC
Vaporized THC (20 mg)
CBD 20
0 mg THC, 20 mg CBD
CBD 20 mg
Vaporized CBD (20 mg)
CBD 40
0 mg THC, 40 mg CBD
CBD 40 mg
Vaporized CBD (40 mg)
CBD 80
0 mg THC, 80 mg CBD
CBD 80 mg
Vaporized CBD (80 mg)
THC with CBD 20
20 mg THC, 20 mg CBD
THC
Vaporized THC (20 mg)
CBD 20 mg
Vaporized CBD (20 mg)
THC with CBD 40
20 mg THC, 40 mg CBD
THC
Vaporized THC (20 mg)
CBD 40 mg
Vaporized CBD (40 mg)
THC with CBD 80
20 mg THC, 80 mg CBD
THC
Vaporized THC (20 mg)
CBD 80 mg
Vaporized CBD (80 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Vaporized Placebo
THC
Vaporized THC (20 mg)
CBD 20 mg
Vaporized CBD (20 mg)
CBD 40 mg
Vaporized CBD (40 mg)
CBD 80 mg
Vaporized CBD (80 mg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Report cannabis use 1-7 days per week over the month prior to screening
* Not currently seeking treatment for their cannabis use
* History of inhaled cannabis use
* Have a Body Mass Index from 18.5 - 34 kg/m2
* Able to perform all study procedures
* Must be using a contraceptive (hormonal or barrier methods)
Exclusion Criteria
* Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
* Report using other illicit drugs in the prior 4 weeks
* Current pain
* Pregnancy
* Currently enrolled in another research protocol
* Not using a contraceptive method (hormonal or barrier methods)
* Insensitivity to the cold water stimulus of the Cold Pressor Test
* Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
* Not able to speak and read English
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ziva D. Cooper, PhD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ziva Cooper, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Los Angeles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Center for Cannabis and Cannabinoids
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
93306
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
24-5306
Identifier Type: -
Identifier Source: org_study_id